CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a precision therapeutics company developing treatments for diseases associated with electrically excitable cells, announced today the appointment of Paul Medeiros as President and Chief Executive Officer of the company. With nearly 25 years of global executive pharmaceutical experience, Mr. Medeiros is a proven business leader with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. He will lead the company’s efforts to bring its first therapeutic candidates into the clinic.

“We are very pleased that Paul is joining our team,” said Mark Evenstad, Chairman of the Board of Q-State. “His perspective, capabilities and broad experience in the biopharmaceutical industry make him an invaluable addition to our company during this period of accelerating advancement in our business.”

“I believe that with its unique technology and outstanding team, Q-State holds tremendous promise for the discovery and development of important new targeted medicines” said Paul Medeiros. “I am thrilled to be leading the company during this exciting time as we rapidly advance our internal and partnered therapeutic programs.”

Mr. Medeiros joins Q-State from Imbrium Therapeutics, where he served as President and founding executive, directing the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment / accelerator firm Greenfield BioVentures. In addition to these roles, Mr. Medeiros has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Mr. Medeiros has served on the board of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. (Read more…) He received his AB with Honors from Brown University and his MBA from Columbia Business School.

About Q-State Biosciences

Q-State Biosciences is a precision therapeutics company based in Cambridge, MA that develops transformative treatments for diseases associated with electrically excitable cells. Q-State applies proprietary human cellular models, unique optogenetic measurement tools and deep, machine learning analytics to discover and optimize new targeted medicines for diseases with high unmet need. For more information, please visit www.qstatebio.com.

Contacts

Media
Shai Biran

[email protected]
+1 781-235-3060

Business Development
Wendell Taylor

[email protected]
+1-617-945-5433

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a precision therapeutics company developing treatments for diseases associated with electrically excitable cells, announced today the appointment of Paul Medeiros as President and Chief Executive Officer of the company. With nearly 25 years of global executive pharmaceutical experience, Mr. Medeiros is a proven business leader with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. He will lead the company’s efforts to bring its first therapeutic candidates into the clinic.

“We are very pleased that Paul is joining our team,” said Mark Evenstad, Chairman of the Board of Q-State. “His perspective, capabilities and broad experience in the biopharmaceutical industry make him an invaluable addition to our company during this period of accelerating advancement in our business.”

“I believe that with its unique technology and outstanding team, Q-State holds tremendous promise for the discovery and development of important new targeted medicines” said Paul Medeiros. “I am thrilled to be leading the company during this exciting time as we rapidly advance our internal and partnered therapeutic programs.”

Mr. Medeiros joins Q-State from Imbrium Therapeutics, where he served as President and founding executive, directing the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment / accelerator firm Greenfield BioVentures. In addition to these roles, Mr. Medeiros has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Mr. Medeiros has served on the board of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. (Read more…) He received his AB with Honors from Brown University and his MBA from Columbia Business School.

About Q-State Biosciences

Q-State Biosciences is a precision therapeutics company based in Cambridge, MA that develops transformative treatments for diseases associated with electrically excitable cells. Q-State applies proprietary human cellular models, unique optogenetic measurement tools and deep, machine learning analytics to discover and optimize new targeted medicines for diseases with high unmet need. For more information, please visit www.qstatebio.com.

Contacts

Media
Shai Biran

[email protected]
+1 781-235-3060

Business Development
Wendell Taylor

[email protected]
+1-617-945-5433